Category - Developments

Developments

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) presented interim data from its Phase 2 (Study II) clinical study at the American Society of Clinical Oncology (ASCO) Genito Urinary Cancer Symposium via a moderated poster...

February 23, 2023

Developments

SenterCare in pact to bring aging-at-home-safely technology to Japan

Closely-held SenterCare, a member of the Trendlines Group of Israel, and Nozomi MedAlliance established an alliance to bring SenterCare’s advanced aging-at-home-safely technology to the Japanese market. SenterCare has...

February 21, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Developments

Freedom Holding to acquire Maxim Group for $400-million

Freedom Holding (NASDAQ:FRHC), a multi-national financial services firm, agreed to acquire Maxim Group and its registered investment advisory affiliate, Maxim Financial Advisors, for a combination of cash and common...

February 17, 2023

Developments

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive (NASDAQ:ARAV) will present updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU)...

February 14, 2023

Developments

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...

February 9, 2023

Developments

Abbott to acquire Cardiovascular Systems for $890-million

Abbott (NYSE:ABT) agreed to acquire Cardiovascular Systems, Inc. (NASDAQ:CSII) for $20 a share or approximately $890-million. Cardiovascular Systems is a leader in devices for atherectomy, a minimally invasive treatment...

February 9, 2023

Developments

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

Germany’s Federal Institute for Drugs and Medical Devices approved NeuroSense Therapeutics’ (NASDAQ:NRSN) clinical trial application to enroll patients in PARADIGM, a Phase 2b study of its lead combination drug...

February 8, 2023

Developments

Annovis Bio to expand Phase 3 PD study of buntanetap to EU

Annovis Bio (NYSE:ANVS) received approval to open 48 clinical trial sits in five European Union countries for its ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (PD). The company is...

February 8, 2023

Developments

SynaptixBio gets FDA rare pediatric disease nod for TUBB4a leukodystrophy

Dr. Dan Williams, CEO and Co-founder The FDA granted a rare pediatric disease (RPD) designation to closely-held SynaptixBio of the UK to develop the first treatment for TUBB4A leukodystrophy, a rare genetic and...

February 7, 2023

Category - Developments

Subscribe